Russian General Prosecutor's Office starts Teva bribery investigation

27 December 2016

The Russian General Prosecutor's Office will check information about the bribes that were allegedly paid by Teva Russia to a certain Russian top official for the assistance in the promotion its products during state tenders for public procurement of drugs in Russia.

This information has already been confirmed by Veronika Skvortsova, Russia’s Minister of Health, report The Pharma Letter’s local correspondent.

The news comes following the revelation last week that Israeli parent company Teva Pharmaceutical Industries (NYSE: TEVA) had reached a $520 million settlement with the US Department of Justice and Securities and Exchange Commission relating to charges of bribing officials in Russia, as well as Ukraine and Mexico.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK